MedPharm, a global contract development organization for topical and transdermal products, has successfully completed a pre-approval inspection by the FDA at its facility in Durham, NC. The inspection took place between January 27-31. The FDA inspectors found the site to be compliant and no Form 483 observations issued.   The inspection was triggered by data generated by MedPharm as part of a client’s ANDA for a generic topical product. The ANDA submission used MedPharm’s in vitro models to demo...